WESTON (dpa-AFX) - Biogen Inc. (BIIB) Friday said its XIRIUS study of cotoretigene toliparvovec failed to meet its primary endpoint in Phase 2/3 in patients with X-linked retinitis pigmentosa or XLRP.
The company further noted that the study obtained positive trends in other pre-specified clinically relevant endpoints, such as a measure of visual acuity under low light conditions.
XLRP is a rare, inherited retinal disease that is associated with progressive vision loss. Cotoretigene toliparvovec or BIIB112 is an investigational AAV8 vector-based gene therapy administered by subretinal injection.
The company also announced a global collaboration and licensing agreement with ViGeneron GmbH to develop and commercialize gene therapy products based on adeno-associated virus vectors.
Copyright RTT News/dpa-AFX
© 2021 AFX News
